Document is current
Any future updates will be listed below
-
Authors
Masaoka, Misa
Yamashiro, Kenji
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 21 August 2025
First Online: 26 September 2025
Declarations
:
: The authors declare no competing interests.
: After switching from aflibercept to faricimab during maintenance treatment for neovascular age-related macular degeneration, faricimab resulted in a longer period of significant reduction in retinal exudative changes than aflibercept, whereas visual acuity remained stable for three months with either treatment.
